The global Animal Antibacterial and Antibiotics Market is projected to grow from approximately USD 4.9 billion in 2024 to ...

Investigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The decision comes just a few months after Bayer reported encouraging results for eliapixant in chronic cough – the same indication sought by Merck for gefapixant – saying it hit its objective ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...